Citations

Clear

4801 citation(s) found for "Yu, Jennifer".

Interactive enhancer hubs (iHUBs) mediate transcriptional reprogramming and adaptive resistance in pancreatic cancer
Hamdan, Feda H. , Abdelrahman, Amro M. , Kutschat, Ana P. , Wang, Xin , Ekstrom, Thomas L. , Jalan‐Sakrikar, Nidhi , Wippel, Catherine Wegner, Taheri, Negar , Tamon, Liezel, Kopp, Waltraut, Aggrey-Fynn, Joana , Bhagwate, Aditya , Lynch, Isaac, Kosinsky, Robyn Laura , Gaedcke, Jochen , Hahn, Stephan A. , Graham, Rondell, Najafova, Zeynab , Heßmann, Elisabeth , Truty, Mark J. , Johnsen, Steven A. , Kutschat, Ana Patricia , Wegner Wippel, Catherine, Bhagwate, Aditya V., Alva-Ruiz, Roberto, Yonkus, Jennifer, Hahn, Stephan A , Siveke, Jens , Johnsen, Steven A , Najafova, Zeynab , Kosinsky, Robyn Laura , Abdelrahman, Amro M , Sakrikar, Nidhi Jalan , Alva‐Ruiz, Roberto , Lynch, Isaac, Yonkus, Jennifer A.

Mayo Clinic

Gut | March 8, 2023 | Volume: 72 | Issue: 6 | Pages: 1174-1185

10.1136/gutjnl-2022-328154 | PMID 36889906 Get It

Objective Pancreatic ductal adenocarcinoma (PDAC) displays a remarkable propensity towards therapy resistance. However, molecular epigenetic and transcriptional mechanisms enabling this are poorly understood. In this study, we aimed to identify novel mechanistic approaches to overcome or prevent resistance in PDAC. Design We used in vitro and in vivo models of resistant PDAC and integrated epigenomic, transcriptomic, nascent RNA and chromatin topology data. We identified a JunD-driven subgroup of enhancers, called interactive hubs (iHUBs), which mediate transcriptional reprogramming and chemoresistance in PDAC. Results iHUBs display characteristics typical for active enhancers (H3K27ac enrichment) in both therapy sensitive and resistant states but exhibit increased interactions and production of enhancer RNA (eRNA) in the resistant state. Notably, deletion of individual iHUBs was sufficient to decrease transcription of target genes and sensitise resistant cells to chemotherapy. Overlapping motif analysis and transcriptional profiling identified the activator protein 1 (AP1) transcription factor JunD as a master transcription factor of these enhancers. JunD depletion decreased iHUB interaction frequency and transcription of target genes. Moreover, targeting either eRNA production or signaling pathways upstream of iHUB activation using clinically tested small molecule inhibitors decreased eRNA production and interaction frequency, and restored chemotherapy responsiveness in vitro and in vivo. Representative iHUB target genes were found to be more expressed in patients with poor response to chemotherapy compared with responsive patients. Conclusion Our findings identify an important role for a subgroup of highly connected enhancers (iHUBs) in regulating chemotherapy response and demonstrate targetability in sensitisation to chemotherapy.
Mechanical Thrombectomy Global Access For Stroke (MT-GLASS): A Mission Thrombectomy (MT-2020 Plus) Study
Asif, Kaiz , Otite, Fadar Oliver , Desai, Shashvat M. , Herial, Nabeel , Inoa, Violiza , Al‐Mufti, Fawaz , Dmytriw, Adam A. , Castonguay, Alicia C. , Khandelwal, Priyank , Potter‐Vig, Jennifer , Szeder, Viktor , Kulman, Tanzila, Masoud, Hesham , Tóth, Gábor , Limaye, Kaustubh , Aroor, Sushanth , Brinjikji, Waleed , Rai, Ansaar , Gebreyohanns, Mehari , Leung, Thomas , Mansour, Malek , Huded, Vikram , Zaidat, Osama O. , Sylaja, PN , Yavagal, Dileep R. , Cirio, Juan , Lylyk, Pedro , Ferrario, Ángel, Plaghos, Luis Lemme, Ibrahim, Wael Hamed, Alnidawi, Firas , Islam, Sirajee Shafiqul, Shahidullah, Mohammad, Saavedra, Víctor Villarroel, Alverne, Francisco Josà Mont’, Magalhães, Pedro , Sirakov, Stanimir , Kalpachki, Rosen, Alioski, Nurfet, Lamou, Eric Gueumekane Bila , Rowe, Daidre, Gayle, Francene , Souza, Romnesh de, Ramos, Cristina , GarcÃa, Amaury, Ali, Amza , Sandy, Sherry , Guzman, Tony Fabian Alvarez, Villarraga, Alejandro, Estrada, Carolina, Pabón, B , Adebayo, Philip , ABDO, GERMAN, S, Nelson Maldonado, Khinikadze, Mirza, Tsiskaridze, Alexander , Syrmos, Νikolaos , Mitsias, Panayiotis , Das, Biplab , Gupta, Vipul , Karapurkar, Anil, Stivastava, M.V.Padma, Alurkar, Anand, Sharma, Arvind , Lahoti, Satish, Kuruttukulam, Gigy , Sari, Ita Muharram , Khassaf, Mustafa Saleem, Nassir, Temeem Majid, Yamagami, Hiroshi , Dababneh, Haitham, Aladham, Farid A., Berdikhojayev, Mynzhylky , Medukhanova, Sabina , Kikano, Raghid, Alaraj, Ali , Ahdab, Rechdi , Zaidi, Wan Asyraf Wan , Kadir, Khairul Azmi Abd, Gongora, Fernando, Jambaldorj, Ariunaa , XXX, Ganbaatar, Shwe, Zarni Myint, Thit, Win Min , RAYO, ERWIN E., Makanjuola, Akintomiwa , Rashid, Umair, Mernes, Ricardo, Paniagua, Osvaldo, GALLO, MARLA, Moquillaza, Manuel, Collantes, Maria Epifania , Mariano, Manuel, Kobayashi, Adam , Rodríguez‐Mercado, Rafael, Guardia, Rodolfo Alcedo, Imam, Yahia , Ahmed, Ayman Z., Al-Jehani, Hosam , Lee, Wickly, Klepanec, Andrej , Brey, Naeem , Rossouw, Anastasia, Silva, Prasad De, Gunasekera, Harsha, Ranawaka, Udaya K. , Osman, Haytham , El-Sadig, Sarah , Suwanwela, Nijasri C., Akarathanawat, Wasan, Tantivatana, Jarturon , Hammami, Nadia, Giray, Semih , Lebedynets, Dmytro , Konotopchik, Stanislav, John, Seby , Hussain, Syed , Novakovic-White, Robin, Perue, Gillian L Gordon, Then, Ryna , Berrutti, Claudio, Crosa, Roberto , Nguyen, Huy Thang, Le, Huynh Vu, vu, Tran thanh, Asif, Kaiz S , Otite, Fadar O , Jadhav, Ashutosh P , Dmytriw, Adam A , Castonguay, Alicia , Khandelwal, Priyank , Szeder, Viktor , Urrutia, Victor C , Masoud, Hesham , Toth, Gabor , Limaye, Kaustubh , Brinjikji, Waleed , Rai, Ansaar , Pandian, Jeyaraj , Leung, Thomas , Mansour, Ossama , Demchuk, Andrew M , Martins, Sheila , Zaidat, Osama O , Huo, Xiaochuan , Campbell, Bruce , Miao, Zhongrong , Saver, Jeffrey , Ortega-Gutierrez, Santiago , Yavagal, Dileep R , Crosa, Roberto , Alaraj, Ali , Al-Mufti, Fawaz , Jadhav, Ashutosh P. , Urrutia, Victor , Pandian, Jeyaraj , Demchuk, Andrew M. , Saver, Jeffrey L. , Arroyo, José, Yan, Bernard , Chandra, Ronil Vikesh , Shahidullah, Mohammad, Alverne, F Mont, Silva, Gisele Sampaio , Shankar, Jai , Stotts, Grant , Ramos, Cristina, Lavados, Pablo M. , Rivera, Rodrigo , Krajina, Antonı́n , Tomek, Aleš , Hassan, Farouk , Khedr, Eman M. , Nadareishvili, Zurab , Roy, Jayanta , Gupta, Vivek , Khurana, Dheeraj , Kumar, Rahul Kewal , Sani, Achmad Firdaus , Sakai, Nobuyuki , Aladham, Farid, Kikano, Raghid , Araúz, Antonio , Góngora‐Rivera, Fernando , Shwe, Zarni Myint, Ranta, Annemarei , Wu, Teddy Y , Owolabi, Mayowa , Ahmad, Saima , Wasay, Mohammad , Alhazzani, Adel Ali , Zeleňák, Kamil , Krastev, Georgi , Frol, Senta , Hammami, Nadia, Sassi, Samia Ben , Özdemi̇r, Atilla Özcan , Конотопчик, С. В., Perue, Gillian Gordon

Mayo Clinic

Circulation | March 8, 2023 | Volume: 147 | Issue: 16 | Pages: 1208-1220

10.1161/circulationaha.122.063366 | PMID 36883458 Get It

Background: Despite the well-established potent benefit of mechanical thrombectomy (MT) for large vessel occlusion (LVO) stroke, access to MT has not been studied globally. We conducted a worldwide survey of countries on 6 continents to define MT access (MTA), the disparities in MTA, and its determinants on a global scale. Methods: Our survey was conducted in 75 countries through the Mission Thrombectomy 2020+ global network between November 22, 2020, and February 28, 2021. The primary end points were the current annual MTA, MT operator availability, and MT center availability. MTA was defined as the estimated proportion of patients with LVO receiving MT in a given region annually. The availability metrics were defined as ([current MT operators×50/current annual number of estimated thrombectomy-eligible LVOs]×100 = MT operator availability) and ([current MT centers×150/current annual number of estimated thrombectomy-eligible LVOs]×100= MT center availability). The metrics used optimal MT volume per operator as 50 and an optimal MT volume per center as 150. Multivariable-adjusted generalized linear models were used to evaluate factors associated with MTA. Results: We received 887 responses from 67 countries. The median global MTA was 2.79% (interquartile range, 0.70–11.74). MTA was <1.0% for 18 (27%) countries and 0 for 7 (10%) countries. There was a 460-fold disparity between the highest and lowest nonzero MTA regions and low-income countries had 88% lower MTA compared with high-income countries. The global MT operator availability was 16.5% of optimal and the MT center availability was 20.8% of optimal. On multivariable regression, country income level (low or lower–middle versus high: odds ratio, 0.08 [95% CI, 0.04–0.12]), MT operator availability (odds ratio, 3.35 [95% CI, 2.07–5.42]), MT center availability (odds ratio, 2.86 [95% CI, 1.84–4.48]), and presence of prehospital acute stroke bypass protocol (odds ratio, 4.00 [95% CI, 1.70–9.42]) were significantly associated with increased odds of MTA. Conclusions: Access to MT on a global level is extremely low, with enormous disparities between countries by income level. The significant determinants of MT access are the country’s per capita gross national income, prehospital LVO triage policy, and MT operator and center availability.
Implementation of genomic medicine for rare disease in a tertiary healthcare system: Mayo Clinic Program for Rare and Undiagnosed Diseases (PRaUD)
Kemppainen, Jennifer L., Vitek, Carolyn R. Rohrer , Whalen, Denise A., Kolbert, Kayla J., Sikkink, Kaitlin J. , Kroc, Sarah A., Kruisselbrink, Teresa , Shupe, Gabrielle F., Knudson, Alyssa K., Burke, Elizabeth , Loftus, Elle C., Bandel, Lorelei A. , Prochnow, Carri A., Mulvihill, Lindsay A., Thomas, Brittany C. , Gamble, Dale M., Graddy, Courtney B., Garzon, Giovanna G. Moreno, Ekpoh, Idara U., Porquera, Eva M. Carmona, Hogan, Marie C. , Ters, Mireille El , Davis, III John M., Vella, Adrian, Kumar, Seema , Creo, Ana L. , Lteif, Aida, Pittock, Siobhán T. , Tebben, Peter J. , Abate, Ejigayehu G., Joshi, Avni Y. , Ristagno, Elizabeth H. , Patnaik, Mrinal S., Sabrowsky, Sonia M., Wierenga, Klaas J. , Keddis, Mira T. , Samadder, N. Jewel , Presutti, R. John , Stephens, Michael C., Roberts, Lewis R. , Faubion, William A. , Driscoll, Sherilyn W. , Selcen, Duygu , Jackson, Lauren , Ortega, Victor E. , Anderson, Sarah , Aoudia, Stacy L., Klee, Eric W. , McAllister, Tammy M., Carmona, Eva M. , Carmona, Eva M , Roberts, Lewis R , Presutti, Richard J , Tebben, Peter , Hogan, Marie C , Vairo, Filippo Pinto e , Burke, Elizabeth M., Fervenza, Fernando C. , Warrington, Kenneth J. , Koster, Matthew J. , Orandi, Amir B. , Basiaga, Matthew L. , Patnaik, Mrinal S., Schimmenti, Lisa A. , Dhamija, Radhika , Robinson, Steven I. , Wong‐Kisiel, Lily C. , Flanagan, Eoin P. , Ramanan, Vijay K. , Mauermann, Michelle L. , Lazaridis, Konstantinos N.

Mayo Clinic

No container title available | March 7, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-2617916/v1 Get It

Abstract Background In the United States, rare disease (RD) is defined as a condition that affects fewer than 200,000 individuals. Collectively, RD affects an estimated 30 million Americans. A significant portion of RD has an underlying genetic cause; however, this may go undiagnosed. To better serve these patients, the Mayo Clinic Program for Rare and Undiagnosed Diseases (PRaUD) was created under the auspices of the Center for Individualized Medicine (CIM) aiming to integrate genomics into subspecialty practice including targeted genetic testing, research, and education. Methods Patients were identified by subspecialty healthcare providers from 11 clinical divisions/departments. Targeted multi-gene panels or custom exome/genome-based panels were utilized. To support the goals of PRaUD, a new clinical service model, the Genetic Testing and Counseling (GTAC) unit, was established to improve access and increase efficiency for genetic test facilitation. The GTAC unit includes genetic counselors, genetic counseling assistants, genetic nurses, and a medical geneticist. Patients receive abbreviated point-of-care genetic counseling and testing through a partnership with subspecialty providers. Results Implementation of PRaUD began in 2018 and GTAC unit launched in 2020 to support program expansion. Currently, 29 RD clinical indications are included in 11 specialty divisions/departments with over 142 referring providers. To date, 1,152 patients have been evaluated with an overall solve rate of 14.1% and as high as 66.7% depending on the phenotype. Noteworthy, 42.7% of the solved or likely solved patients underwent changes in medical management and outcome based on genetic test results. Conclusion Implementation of PRaUD and GTAC have enabled subspecialty practices advance expertise in RD where genetic counselors have not historically been embedded in practice. Democratizing access to genetic testing and counseling can broaden the reach of patients with RD and increase the diagnostic yield of such indications leading to better medical management as well as expanding research opportunities.
Community-Onset Bacterial Coinfection in Children Critically Ill With Severe Acute Respiratory Syndrome Coronavirus 2 Infection
酒井, 忠雄, Nakamura, Mari M, Young, Cameron C, Newhams, Margaret M, Halasa, Natasha B, Reed, J Nelson, Fitzgerald, Julie C, Spinella, Philip C, Soma, Vijaya L, Walker, Tracie C, Loftis, Laura L, Maddux, Aline B, Kong, Michele, Rowan, Courtney M, Hobbs, Charlotte V, Schuster, Jennifer E, Riggs, Becky J, McLaughlin, Gwenn E, Michelson, Kelly N, Hall, Mark W, Babbitt, Christopher J, Cvijanovich, Natalie Z, Zinter, Matt S, Maamari, Mia, Schwarz, Adam J, Singh, Aalok R, Flori, Heidi R, Gertz, Shira J, Staat, Mary A, Giuliano, John S, Hymes, Saul R, Clouser, Katharine N, McGuire, John, Carroll, Christopher L, Thomas, Neal J, Levy, Emily R, Randolph, Adrienne G, Randolph, Adrienne G. , Spinella, Philip C. , Levy, Emily R. , Staat, Mary Allen , Young, Cameron C. , McGuire, John K. , Gertz, Shira J. , Kong, Michele , Zinter, Matt S. , Moffitt, Kristin , Malloch, Lacy , Moffitt, Kristin L , Young, Cameron C , Hobbs, Charlotte V , Randolph, Adrienne G , Levy, Emily R , Spinella, Philip C , Kong, Michele , Staat, Mary A , Gertz, Shira J , Nakamura, Mari M, Newhams, Margaret M, Halasa, Natasha B, Reed, J Nelson, Fitzgerald, Julie C, Spinella, Philip C, Soma, Vijaya L, Walker, Tracie C, Loftis, Laura L, Maddux, Aline B, Kong, Michele, Rowan, Courtney M, Schuster, Jennifer E, Riggs, Becky J, McLaughlin, Gwenn E, Michelson, Kelly N, Hall, Mark W, Babbitt, Christopher J, Cvijanovich, Natalie Z, Zinter, Matt S, Maamari, Mia, Schwarz, Adam J, Singh, Aalok R, Flori, Heidi R, Gertz, Shira J, Staat, Mary A, Giuliano, John S, Hymes, Saul R, Clouser, Katharine N, McGuire, John, Carroll, Christopher L, Thomas, Neal J, Levy, Emily R

Mayo Clinic

Open Forum Infectious Diseases | March 7, 2023 | Volume: 10 | Issue: 3 | Pages: No page available

10.1093/ofid/ofad122 | PMID 36968962 Get It

AbstractBackgroundCommunity-onset bacterial coinfection in adults hospitalized with coronavirus disease 2019 (COVID-19) is reportedly uncommon, though empiric antibiotic use has been high. However, data regarding empiric antibiotic use and bacterial coinfection in children with critical illness from COVID-19 are scarce.MethodsWe evaluated children and adolescents aged &lt;19 years admitted to a pediatric intensive care or high-acuity unit for COVID-19 between March and December 2020. Based on qualifying microbiology results from the first 3 days of admission, we adjudicated whether patients had community-onset bacterial coinfection. We compared demographic and clinical characteristics of those who did and did not (1) receive antibiotics and (2) have bacterial coinfection early in admission. Using Poisson regression models, we assessed factors associated with these outcomes.ResultsOf the 532 patients, 63.3% received empiric antibiotics, but only 7.1% had bacterial coinfection, and only 3.0% had respiratory bacterial coinfection. In multivariable analyses, empiric antibiotics were more likely to be prescribed for immunocompromised patients (adjusted relative risk [aRR], 1.34 [95% confidence interval {CI}, 1.01–1.79]), those requiring any respiratory support except mechanical ventilation (aRR, 1.41 [95% CI, 1.05–1.90]), or those requiring invasive mechanical ventilation (aRR, 1.83 [95% CI, 1.36–2.47]) (compared with no respiratory support). The presence of a pulmonary comorbidity other than asthma (aRR, 2.31 [95% CI, 1.15–4.62]) was associated with bacterial coinfection.ConclusionsCommunity-onset bacterial coinfection in children with critical COVID-19 is infrequent, but empiric antibiotics are commonly prescribed. These findings inform antimicrobial use and support rapid de-escalation when evaluation shows coinfection is unlikely.
Iron deficiency in pulmonary vascular disease: pathophysiological and clinical implications
Martens, Pieter , Yu, Shilin , Larive, Brett , Erzurum, Serpil C. , Farha, Samar , Finet, J. Emanuel , Grünig, Gabriele , Hill, Nicholas S. , Jacob, Miriam , Kwon, Deborah , Park, Margaret , Wilcox, Jennifer , Tang, W.H. Wilson , Group, the PVDOMICS Study, Horn, Evelyn M , Tang, W H Wilson , Wilcox, Jennifer D , Borlaug, Barry A. , Hemnes, Anna R. , Horn, Evelyn M. , Rischard, Franz , Rosenzweig, Erika B. , Group, the PVDOMICS Study

Mayo Clinic

European Heart Journal | March 7, 2023 | Volume: 44 | Issue: 22 | Pages: 1979-1991

10.1093/eurheartj/ehad149 | PMID 36879444 Get It

Abstract Aims Iron deficiency is common in pulmonary hypertension, but its clinical significance and optimal definition remain unclear. Methods and results Phenotypic data for 1028 patients enrolled in the Redefining Pulmonary Hypertension through Pulmonary Vascular Disease Phenomics study were analyzed. Iron deficiency was defined using the conventional heart failure definition and also based upon optimal cut-points associated with impaired peak oxygen consumption (peakVO2), 6-min walk test distance, and 36-Item Short Form Survey (SF-36) scores. The relationships between iron deficiency and cardiac and pulmonary vascular function and structure and outcomes were assessed. The heart failure definition of iron deficiency endorsed by pulmonary hypertension guidelines did not identify patients with reduced peakVO2, 6-min walk test, and SF-36 (P &gt; 0.208 for all), but defining iron deficiency as transferrin saturation (TSAT) &lt;21% did. Compared to those with TSAT ≥21%, patients with TSAT &lt;21% demonstrated lower peakVO2 [absolute difference: −1.89 (−2.73 to −1.04) mL/kg/min], 6-min walk test distance [absolute difference: −34 (−51 to −17) m], and SF-36 physical component score [absolute difference: −2.5 (−1.3 to −3.8)] after adjusting for age, sex, and hemoglobin (all P &lt; 0.001). Patients with a TSAT &lt;21% had more right ventricular remodeling on cardiac magnetic resonance but similar pulmonary vascular resistance on catheterization. Transferrin saturation &lt;21% was also associated with increased mortality risk (hazard ratio 1.63, 95% confidence interval 1.13–2.34; P = 0.009) after adjusting for sex, age, hemoglobin, and N-terminal pro-B-type natriuretic peptide. Conclusion The definition of iron deficiency in the 2022 European Society of Cardiology (ESC)/European Respiratory Society (ERS) pulmonary hypertension guidelines does not identify patients with lower exercise capacity or functional status, while a definition of TSAT &lt;21% identifies patients with lower exercise capacity, worse functional status, right heart remodeling, and adverse clinical outcomes.
International consensus statement on allergy and rhinology: Allergic rhinitis – 2023
Wise, Sarah K. , Damask, Cecelia, Ebert, Charles S. , Levy, Joshua M. , Lin, Sandra Y. , Luong, Amber , Rodriguez, Kenneth , Sedaghat, Ahmad R. , Toskala, Elina , Akdiş, Cezmi A. , Ansotegui, Ignacio J. , Azar, Antoine , Baroody, Fuad M. , Benninger, Michael S. , Casale, Thomas B. , Chaaban, Mohamad R. , Chew, Fook Tim , Chambliss, Jeffrey , Cianferoni, Antonella , Čustović, Adnan , Davis, Elizabeth Mahoney , DelGaudio, John M. , Flanagan, Carrie E. , Franzese, Christine B., Gill, Amarbir S. , Halderman, Ashleigh A. , Joe, Stephanie, Joshi, Shyam , Kuruvilla, Merin , Kim, Jean , Klein, Adam M. , Krouse, Helene J. , Lang, David M. , Laury, Adrienne M., Lee, Victoria S. , Loftus, Patricia A. , Marzouk, Haidy, Mims, James W., Oppenheimer, John , Orlandi, Richard R. , Phillips, Katie M. , Raymond, Mallory , Ryan, Matthew W., Sastre, J. , Schlosser, Rodney J. , Shaker, Marcus , Smith, Kristine A. , Soyka, Michael , Tang, Monica , Tantilipikorn, Pongsakorn , Taw, Malcolm B., Tversky, Jody , Tyler, Matthew A. , Veling, Maria C., Wallace, Dana , White, Andrew A. , Roland, Lauren T , Levy, Joshua M , Luong, Amber U , Sedaghat, Ahmad R , Villwock, Jennifer , Abdullah, Baharudin , Alt, Jeremiah A , Chaaban, Mohamad R , Gill, Amarbir , Kuruvilla, Merin Elizabeth , Kim, Jean , Kuan, Edward C , Lee, Victoria S , Marcus, Sonya , Mattos, Jose , McCoul, Edward D , Nayak, Jayakar V , Orlandi, Richard , Schuman, Theodore A , Smith, Kristine , Soyka, Michael B , Tantilipikorn, Pongsakorn , Tyler, Matthew A , Zhang, Luo , Schlosser, Rodney J , Chew, Fook Tim , Casale, Thomas , Alt, Jeremiah A. , Bernstein, Jonathan A. , Brook, Christopher D. , Campbell, Raewyn Gay , Ellis, Anne K. , Fokkens, Wytske Johanna , Greenhawt, Matthew , Hohlfeld, Jens Michael , Incorvaia, Cristoforo , Larenas‐Linnemann, Désirée E. , Lechner, Matt , Lee, Stella E. , Mattos, José L. , McCoul, Edward D. , Melén, Erik , Mullol, Joaquim , Nayak, Jayakar V. , Platt, Michael P. , Ramanathan, Murugappan , Raymond, Mallory J , Rhee, Chae‐Seo , Reitsma, Sietze , Sheikh, Aziz , Takashima, Masayoshi , Wang, De Yun , Zhang, Luo

Mayo Clinic

International Forum of Allergy & Rhinology | March 6, 2023 | Volume: 13 | Issue: 4 | Pages: 293-859

10.1002/alr.23090 | PMID 36878860 Get It

Abstract Background In the 5 years that have passed since the publication of the 2018 International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (ICAR‐Allergic Rhinitis 2018), the literature has expanded substantially. The ICAR‐Allergic Rhinitis 2023 update presents 144 individual topics on allergic rhinitis (AR), expanded by over 40 topics from the 2018 document. Originally presented topics from 2018 have also been reviewed and updated. The executive summary highlights key evidence‐based findings and recommendation from the full document. Methods ICAR‐Allergic Rhinitis 2023 employed established evidence‐based review with recommendation (EBRR) methodology to individually evaluate each topic. Stepwise iterative peer review and consensus was performed for each topic. The final document was then collated and includes the results of this work. Results ICAR‐Allergic Rhinitis 2023 includes 10 major content areas and 144 individual topics related to AR. For a substantial proportion of topics included, an aggregate grade of evidence is presented, which is determined by collating the levels of evidence for each available study identified in the literature. For topics in which a diagnostic or therapeutic intervention is considered, a recommendation summary is presented, which considers the aggregate grade of evidence, benefit, harm, and cost. Conclusion The ICAR‐Allergic Rhinitis 2023 update provides a comprehensive evaluation of AR and the currently available evidence. It is this evidence that contributes to our current knowledge base and recommendations for patient evaluation and treatment.
The influence of anatomic stage and receptor status on first recurrence for breast cancer within 5 years (AFT‐01)
Neuman, Heather B. , Schumacher, Jessica R. , Edge, Stephen B. , Ruddy, Kathryn J. , Partridge, Ann H. , Hanlon, Bret M. , Le‐Rademacher, Jennifer , Yang, Dou‐Yan , Havlena, Jeffrey , Greenberg, Caprice C. , Hanlon, Bret M , Le-Rademacher, Jennifer G , Partridge, Ann H , Yu, Menggang , Vanness, David J. , Strand, Carrie

Mayo Clinic

Cancer | March 6, 2023 | Volume: 129 | Issue: 9 | Pages: 1351-1360

10.1002/cncr.34656 | PMID 36872873 Get It

AbstractBackgroundRisk‐stratified follow‐up guidelines that account for the absolute risk and timing of recurrence may improve the quality and efficiency of breast cancer follow‐up. The objective of this study was to assess the relationship of anatomic stage and receptor status with timing of the first recurrence for patients with local‐regional breast cancer and generate risk‐stratified follow‐up recommendations.MethodsThe authors conducted a secondary analysis of 8007 patients with stage I–III breast cancer who enrolled in nine Alliance legacy clinical trials from 1997 to 2013 (ClinicalTrials.gov identifier NCT02171078). Patients who received standard‐of‐care therapy were included. Patients who were missing stage or receptor status were excluded. The primary outcome was days from the earliest treatment start date to the date of first recurrence. The primary explanatory variable was anatomic stage. The analysis was stratified by receptor type. Cox proportional‐hazards regression models produced cumulative probabilities of recurrence. A dynamic programming algorithm approach was used to optimize the timing of follow‐up intervals based on the timing of recurrence events.ResultsThe time to first recurrence varied significantly between receptor types (p < .0001). Within each receptor type, stage influenced the time to recurrence (p < .0001). The risk of recurrence was highest and occurred earliest for estrogen receptor (ER)‐negative/progesterone receptor (PR)‐negative/Her2neu‐negative tumors (stage III; 5‐year probability of recurrence, 45.5%). The risk of recurrence was lower for ER‐positive/PR‐positive/Her2neu‐positive tumors (stage III; 5‐year probability of recurrence, 15.3%), with recurrences distributed over time. Model‐generated follow‐up recommendations by stage and receptor type were created.ConclusionsThis study supports considering both anatomic stage and receptor status in follow‐up recommendations. The implementation of risk‐stratified guidelines based on these data has the potential to improve the quality and efficiency of follow‐up.
Vaccine Hesitancy in Mississippi: Does Political Ideology Muddy the Waters?
Evans, Marion W. , Wajpe, Abhishek S. , Wari, Eki, Aras, Sermin , Lemacks, Jennifer

Mayo Clinic

Journal of Primary Care & Community Health | March 5, 2023 | Volume: 14 | Issue: No issue available | Pages: No page available

10.1177/21501319231158518 | PMID 36852739 Get It

During the SARS-CoV2 pandemic vaccines were made available at a rapid pace in the United States (US) with support from the government. In Mississippi, vaccine hesitancy was marked. Across the country many areas of the US demonstrated reduced uptake regarding this specific vaccine due to a variety of reasons. Even with the efficacy of the vaccine indicative of a significant level of protection from mortality and serious morbidity, vaccine uptake and hesitancy were a significant concern. This study surveyed Mississippians on their willingness to take the vaccine or not, and in particular, investigated political ideology as a reason for vaccine hesitancy. Data was collected via an online survey and 589 adults (>18 years) responded. Those self-identifying as “Republican” were more than twice as likely to disagree that not getting the vaccine was a risk to their health and others (OR = 2.07, 95% CI 1.70, 2.54) as those who identified as “Democrat or independent” voters. Future health promotion efforts should specifically attempt to address this group in a more effective manner.